Form 4 for RANI Rani Therapeutics Holdings, Inc.
Accepted 2024-12-10 00:00:00 ET · period of report 2024-12-09 · accession 0000950170-24-134828 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-10 | 2024-12-09 | RANI | Imran Talat | CEO, Dir | P - Purchase | $1.94 | +10.3K | 494.8K | +2% | +$20.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2024-12-09 | P | A | 10,296 | $1.94 | 494,751 | D | — | — | (F1) Includes 12,343 shares held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |